National registry study on adult pulmonary Langerhans cell histiocytosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the long-term outcomes, particularly survival, of adult patients diagnosed with pulmonary Langerhans cell histiocytosis (PLCH). It is the first prospective cohort study in this field, utilizing a nationwide registry in France to gather data from a large cohort of PLCH patients. Participants will be followed over an extended period to identify risk factors that influence long-term outcomes. The study will rely on standard care interventions while focusing on observational data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>= 18 years
* Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses

Exclusion Criteria:

\-

Where it's running

• French national reference centre for Histiocytoses
  Paris, France Recruiting

Study contacts

• Study coordinator: Abdellatif TAZI, MD PhD
• Email: abdellatif.tazi@aphp.fr
• Phone: 142499198

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying biomarkers in adult Langerhans cell histiocytosis

  This study is trying to see if certain gene changes in blood samples can help doctors better understand and manage Langerhans cell histiocytosis in adults.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06197204

• Follow-up on health outcomes in patients with histiocytic disorders

  This study looks at the long-term health effects of histiocytic disorders on around 6000 patients to see how these conditions impact their overall well-being and quality of life.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT05915208

• Evaluating BDTX-4933 for patients with specific cancer mutations

  This study is testing a new drug called BDTX-4933 to see if it can help adults with advanced cancers that have certain gene mutations feel better and improve their treatment options.

  Recruiting at 34 sites Phase 1/2 Servier · Gilbert, Arizona and 48 other locations · NCT05786924

• Low-dose cytarabine combined with thalidomide for adults with newly diagnosed LCH

  This trial tests whether combining low-dose cytarabine with thalidomide is safe and effective for adults newly diagnosed with multisystem or multifocal Langerhans cell histiocytosis.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07187193

• Targeted treatment for Langerhans Cell Histiocytosis using trametinib

  This study is testing if trametinib, a new targeted therapy, can help children with Langerhans Cell Histiocytosis feel better and avoid the harsh side effects of traditional chemotherapy.

  Recruiting Phase 2 Cook Children's Health Care System · Fort Worth, Texas · NCT06582745

• Evaluating FCN-159 for treating pediatric patients with recurrent LCH

  This study is testing a new medication called FCN-159 to see if it can help children aged 2 to 16 with recurring Langerhans cell histiocytosis feel better.

  Recruiting at 2 sites Phase 2 Fosunpharma · Beijing, Beijing Municipality and 10 other locations · NCT05997602

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.